REFERENCES
1. Naaber P, Tserel L, Kangro K, et al. Dynamics of antibody response to
BNT162b2 vaccine after six months: a longitudinal prospective study.Lancet Reg Health Eur. 2021;10:100208.
2. Lim WW, Mak L, Leung GM, Cowling BJ, Peiris M. Comparative
immunogenicity of mRNA and inactivated vaccines against COVID-19.Lancet Microbe. 2021;2(9):e423.
3. Barros-Martins J, Hammerschmidt SI, Cossmann A, et al. Immune
responses against SARS-CoV-2 variants after heterologous and homologous
ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat Med.2021;27(9):1525-1529.
4. Tanriover MD, Doganay HL, Akova M, et al. Efficacy and safety of an
inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results
of a double-blind, randomised, placebo-controlled, phase 3 trial in
Turkey. Lancet. 2021;398(10296):213-222.
5. Jara A, Undurraga EA, Gonzalez C, et al. Effectiveness of an
Inactivated SARS-CoV-2 Vaccine in Chile. N Engl J Med.2021;385(10):875-884.
6. Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and
immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults
aged 18-59 years: a randomised, double-blind, placebo-controlled, phase
1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181-192.
7. Fuss IJ, Kanof ME, Smith PD, Zola H. Isolation of whole mononuclear
cells from peripheral blood and cord blood. Curr Protoc Immunol.2009;Chapter 7:Unit7 1.
8. Wang Z, Yang X, Zhong J, et al. Exposure to SARS-CoV-2 generates
T-cell memory in the absence of a detectable viral infection. Nat
Commun. 2021;12(1):1724.
9. Mendoza EJ, Manguiat K, Wood H, Drebot M. Two Detailed Plaque Assay
Protocols for the Quantification of Infectious SARS-CoV-2. Curr
Protoc Microbiol. 2020;57(1):ecpmc105.
10. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels
are highly predictive of immune protection from symptomatic SARS-CoV-2
infection. Nat Med. 2021;27(7):1205-1211.
11. Cao Y, Hao X, Wang X, et al. Humoral immunogenicity and
reactogenicity of CoronaVac or ZF2001 booster after two doses of
inactivated vaccine. Cell Res. 2022;32(1):107-109.
12. Wang K, Cao Y, Zhou Y, et al. A third dose of inactivated vaccine
augments the potency, breadth, and duration of anamnestic responses
against SARS-CoV-2. medRxiv. 2021:2021.2009.2002.21261735.
13. Lu L, Mok BW, Chen LL, et al. Neutralization of SARS-CoV-2 Omicron
variant by sera from BNT162b2 or Coronavac vaccine recipients.Clin Infect Dis. 2021.
14. Pérez-Then E, Lucas C, Monteiro VS, et al. Immunogenicity of
heterologous BNT162b2 booster in fully vaccinated individuals with
CoronaVac against SARS-CoV-2 variants Delta and Omicron: the Dominican
Republic Experience. medRxiv. 2021:2021.2012.2027.21268459.
15. Tan AT, Linster M, Tan CW, et al. Early induction of functional
SARS-CoV-2-specific T cells associates with rapid viral clearance and
mild disease in COVID-19 patients. Cell Rep. 2021;34(6):108728.
16. Sahin U, Muik A, Vogler I, et al. BNT162b2 vaccine induces
neutralizing antibodies and poly-specific T cells in humans.Nature. 2021;595(7868):572-577.
17. Mok CKP, Cohen CA, Cheng SMS, et al. Comparison of the
immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong.Respirology. 2021.
18. Nguyen THO, Rowntree LC, Petersen J, et al. CD8(+) T cells specific
for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive
precursor frequency and TCR promiscuity. Immunity.2021;54(5):1066-1082 e1065.
19. Prendecki M, Clarke C, Brown J, et al. Effect of previous SARS-CoV-2
infection on humoral and T-cell responses to single-dose BNT162b2
vaccine. Lancet. 2021;397(10280):1178-1181.
20. Yalcin TY, Topcu DI, Dogan O, et al. Immunogenicity after two doses
of inactivated virus vaccine in healthcare workers with and without
previous COVID-19 infection: Prospective observational study. J
Med Virol. 2022;94(1):279-286.